Our Therapeutic
Pipeline

Developing Innovative Treg Cell Therapies for Autoimmune Diseases

Learn more

PIPELINE OVERVIEW

Our Therapeutic
Focus

Developing a robust pipeline of Treg cell therapies with the potential to transform the treatment of autoimmune diseases.

Our programs target significant unmet medical needs, with a focus on both prevalent and challenging conditions.

Therapeutic Area & Name
Indication
DISCOVERY
PRECLINICAL
PHASE I
PHASE II
PHASE III
Type 1 diabetes
PTG-007+ / rituximab
Presymptomatic (stage 1)
Multiple sclerosis
PTG-007+ / commonly used MS drug
Primary progressive (PPMS)
Neuroinflammation
CAR-TREG
Multiple sclerosis
 
Amyotrophic Lateral Sclerosis

PIPELINE: T1D

Type 1 Diabetes
Program

Our approach focuses on preserving beta-cell function and preventing or slowing disease progression, particularly in early stages of the disease.

Immuthera is advancing Treg cell therapies to address Type 1 Diabetes (T1D), a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas

01

PTG-007

PTG-007 is being evaluated in clinical trials for its ability to protect beta cells and delay the progression of T1D

02

Next-Generation T1D Therapies

Immuthera is also exploring next-generation approaches, including antigen-specific Tregs and immunomodulatory strategies, to develop even more targeted and effective treatments for T1D.

PIPELINE: MS AND ALS

Neuroinflammatory
Diseases

Immuthera is also developing Treg cell therapies to treat neuroinflammatory diseases.

Including Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS), debilitating conditions characterized by inflammation and damage to the nervous system

01

Multiple Sclerosis (MS)

Our MS program is investigating the potential of Treg therapies to reduce inflammation and protect against further neurological damage in primary progressive Multiple Sclerosis (PPMS). Our previous clinical study showed that Tregs given intrathecally can completely arrest progression one year after treatment as shown by volume and number of plaques via MRI.

02

Next Generation Neuroinflammatory Immunotherapies

Immuthera is also exploring next-generation approaches, including antigen-specific Tregs and immunomodulatory strategies, to develop even more targeted and effective treatments for T1D.

EXPANDING OUR PIPELINE

Leveraging the versatility of Treg cell therapy to address a wide range of autoimmune diseases. We are actively exploring new indications and innovative approaches to expand our pipeline and bring transformative therapies to more patients.

PUBLICATIONS

Major publications

2024
PD-1 Receptor (+) T cells are associated with the efficacy of the combined treatment with regulatory t cells and rituximab in type 1 diabetes children via regulatory t cells suppressive activity amelioration
Download PDF
2024
Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity
Download PDF
2022
Combined therapy with CD4+CD25highCD127 T regulatory cells and anti-CD20 antibody in recent-onset type 1 diabetes is superior to monotherapy: Randomized phase I/II trial
Download PDF
2022
Mesenchymal stem cells transfer mitochondria to allogeneic TREGs in an HLA-dependent manner improving their immunosuppressive activity
Download PDF
2021
Administration of CD4+CD25 high CD127−FoxP3+ Regulatory T Cells for Relapsing‑Remitting Multiple Sclerosis: A Phase 1 Study
Download PDF
2021
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
Download PDF
2020
Antigen-reactive regulatory T cells can be expanded in vitro with monocytes and anti-CD28 and anti-CD154 antibodies
Download PDF
2020
Proinsulin-­specific T regulatory cells may control immune responses in type 1 diabetes: implications for adoptive therapy
Download PDF
2018
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization
Download PDF
2017
Cell-Based Therapies with T Regulatory Cells
Download PDF
2017
Mild hypothermia provides TREG stability
Download PDF
2016
Factors affecting long‑term efficacy of T regulatory cell‑based therapy in type 1 diabetes
Download PDF
2015
Hurdles in therapy with regulatory T cells
Download PDF
2014
Therapy of type 1 diabetes with CD4+ CD25 high CD127-regulatory T cells prolongs survival of pancreatic islets — Results of one year follow-up
Download PDF
2012
Administration of CD4+CD25 high CD1272 Regulatory T Cells Preserves b-Cell Function in Type 1 Diabetes in Children
Download PDF
2011
The Time Is Crucial for Ex Vivo Expansion of T Regulatory Cells for Therapy
Download PDF
2009
First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− Tregulatory cells
Download PDF
2008
Ex Vivo Expansion of CD4+CD25+ T Regulatory Cells for Immunosuppressive Therapy
Download PDF